These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 21726969

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Central Nervous Involvement in Patients with Fukuyama Congenital Muscular Dystrophy].
    Ishigaki K.
    Brain Nerve; 2016 Feb; 68(2):119-27. PubMed ID: 26873231
    [Abstract] [Full Text] [Related]

  • 5. A Portuguese case of Fukuyama congenital muscular dystrophy caused by a multi-exonic duplication in the fukutin gene.
    Costa C, Oliveira J, Gonçalves A, Santos R, Bronze-da-Rocha E, Rebelo O, Pais RP, Fineza I.
    Neuromuscul Disord; 2013 Jul; 23(7):557-61. PubMed ID: 23582336
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Peripheral nerve involvement in fukuyama congenital muscular dystrophy: a case report.
    Jang DH, Sung IY, Ko TS.
    J Child Neurol; 2013 Jan; 28(1):132-7. PubMed ID: 22378666
    [Abstract] [Full Text] [Related]

  • 9. Phenotypic spectrum of Fukutinopathy: most severe phenotype of Fukutinopathy.
    Yoshioka M.
    Brain Dev; 2009 Jun; 31(6):419-22. PubMed ID: 18834683
    [Abstract] [Full Text] [Related]

  • 10. The gross motor function measure is valid for Fukuyama congenital muscular dystrophy.
    Sato T, Adachi M, Nakamura K, Zushi M, Goto K, Murakami T, Ishiguro K, Shichiji M, Saito K, Ikai T, Osawa M, Kondo I, Nagata S, Ishigaki K.
    Neuromuscul Disord; 2017 Jan; 27(1):45-49. PubMed ID: 27818010
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Urinary titin as a biomarker in Fukuyama congenital muscular dystrophy.
    Sato T, Awano H, Ishiguro K, Shichiji M, Murakami T, Shirakawa T, Matsuo M, Nagata S, Ishigaki K.
    Neuromuscul Disord; 2021 Mar; 31(3):194-197. PubMed ID: 33563515
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant.
    Enkhjargal S, Sugahara K, Khaledian B, Nagasaka M, Inagaki H, Kurahashi H, Koshimizu H, Toda T, Taniguchi-Ikeda M.
    Hum Mol Genet; 2023 Apr 06; 32(8):1301-1312. PubMed ID: 36426838
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Deep-intronic variant of fukutin is the most prevalent point mutation of Fukuyama congenital muscular dystrophy in Japan.
    Kobayashi K, Kato R, Kondo-Iida E, Taniguchi-Ikeda M, Osawa M, Saito K, Toda T.
    J Hum Genet; 2017 Nov 06; 62(11):945-948. PubMed ID: 28680109
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.